比较分析左西孟旦与米力农治疗老年顽固性心力衰竭临床疗效  

Comparative Analysis of the Clinical Efficacy of Levosimendan and Milrinone in the Treatment of Refractory Heart Failure in the Elderly

作　　者：刘磊磊[1] LIU Lei-lei(Department of Cardiology, First People's Hospital of Tancheng County, Linyi, Shandong Province, 276199 China)

机构地区：[1]郯城县第一人民医院心血管内科

出　　处：《中外医疗》2019年第14期11-13,共3页China & Foreign Medical Treatment

摘　　要：目的比较顽固性心力衰竭(顽固性心衰)老年患者分别施予米力农、左西孟旦进行治疗的疗效。方法80例研究对象均为方便选取该院心内科收治的顽固性心衰老年患者,纳入时间为2017年7月—2018年7月,将其中单纯实施米力农治疗的40例为A组,另外施予左西孟旦治疗的40例为B组,对比其疗效。结果B组治疗后的LVEF、SV与BNP、QOL评分以及6MWT均优于A组,且B组治疗的总有效率是87.50%,较A组的67.50%高,B组再次住院率为12.50%,较A组的35.00%低,差异有统计学意义(P<0.05)。结论与米力农相比较,左西孟旦治疗顽固性心衰的疗效更为显著,价值更高。Objective To compare the efficacy of milrinone and levosimendan in the treatment of refractory heart failure (refractory heart failure) in elderly patients. Methods 80 patients were convenient selected and enrolled in the elderly with refractory heart failure admitted to our hospital. The time of enrollment was from July 2017 to July 2018. 40 patients who underwent milrinone treatment alone were included in group A. 40 patients who were treated with levosimendan were given group B and their effects were compared. Results The LVEF, SV and BNP, QOL scores and 6MWT were better in group B than in group A, and the total effective rate in group B was 87.50%, which was higher than 67.50% in group A. The rate of re-hospitalization in group B was 12.50%, which was lower than the 35.00% of the A group, and there was a statistical difference(P<0.05). Conclusion Compared with milrinone, levosimendan is more effective in treating refractory heart failure and has higher value.

关 键 词：老年患者 顽固性心衰 左西孟旦 米力农 临床疗效 

分 类 号：R4[医药卫生—临床医学]